ProGen

296160 · KONEX · South Korea

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
GLP-1/GLP-2 receptor (dual)Protein / enzyme therapeutic
ObesityType 2 Diabetes
Phase 1
GLP-1/GLP-2 receptor (dual)
Indication not yet linked

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
May 2027 (1)
PG-102Phase 2Type 2 Diabetes
Est. primary completion 2027-05 · NCT07677891 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 February 2026Topline resultPG-102ProGen reports Phase 2a topline of PG-102 in type 2 diabetes: HbA1c down up to 1.44 points at 14 weeks
ProGen · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3————report ↗